Fund managers holding healthcare and pharmaceutical stocks have questioned the US government's decision to support a waiver on Covid vaccine patents, claiming the move is unlikely to significantly boost vaccine production and could undermine faith in intellectual property law.

The US said on 5 May it would support a temporary suspension of intellectual property rights for Covid 19 vaccines, a suggestion which was tabled by India and South Africa within the World Trade Organisation last year.